TY - JOUR T1 - Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary–renal syndrome JF - BMJ Case Reports DO - 10.1136/bcr-2018-227161 VL - 2018 SP - bcr-2018-227161 AU - Narothama Reddy Aeddula AU - Samata Pathireddy AU - Asif Ansari AU - Peter J Juran Y1 - 2018/12/06 UR - http://casereports.bmj.com/content/2018/bcr-2018-227161.abstract N2 - Hydralazine, a vasodilator, is commonly used as an adjunctive treatment for moderate to severe hypertension, heart failure and hypertensive emergencies in pregnancy. Hydralazine-induced lupus was first described in 1953. Clinical presentation ranges from arthralgia, myalgia, petechiae, or rash to single or multiorgan involvement. An occurrence of systemic vasculitis is a rare complication. When presented as the pulmonary–renal syndrome, it could have a rapidly progressive course which can be fatal. Here, we describe a case of hydralazine-associated rapidly progressive glomerulonephritis and pulmonary haemorrhage. We use this case to review the current literature and discuss and highlight the importance of a high degree of clinical acumen, early diagnosis and prompt treatment for better clinical outcomes. ER -